Mirikizumab
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Crohn's Disease
Conditions
Crohn's Disease
Trial Timeline
Mar 13, 2024 → Apr 1, 2028
NCT ID
NCT05509777About Mirikizumab
Mirikizumab is a phase 3 stage product being developed by Eli Lilly for Crohn's Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05509777. Target conditions include Crohn's Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07446101 | Phase 1 | Recruiting |
| NCT07059130 | Approved | Recruiting |
| NCT05509777 | Phase 3 | Recruiting |
| NCT05644353 | Phase 1 | Completed |
| NCT05515601 | Phase 1 | Completed |
| NCT04548219 | Phase 1 | Completed |
| NCT04232553 | Phase 3 | Active |
| NCT04004611 | Phase 2 | Completed |
| NCT03556202 | Phase 3 | Terminated |
| NCT03519945 | Phase 3 | Active |
Competing Products
20 competing products in Crohn's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CT-P13 + Remicade | Celltrion | Phase 3 | 77 |
| CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 | Celltrion | Phase 1 | 33 |
| CT-P13 SC (Infliximab) | Celltrion | Phase 3 | 77 |
| CP-461 | Astellas Pharma | Phase 2 | 52 |
| E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kg | Eisai | Phase 1/2 | 41 |
| E6011 + Placebo | Eisai | Phase 2 | 52 |
| E6011 + Placebo | Eisai | Phase 1 | 33 |
| adalimumab + adalimumab + placebo | Eisai | Phase 2/3 | 65 |
| adalimumab | Eisai | Phase 2/3 | 65 |
| Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + Placebo | Eli Lilly | Phase 3 | 77 |
| Mirikizumab + Mirikizumab + Tirzepatide + Placebo | Eli Lilly | Phase 3 | 77 |
| Mirikizumab + Placebo | Eli Lilly | Phase 2 | 52 |
| Mirikizumab | Eli Lilly | Phase 3 | 77 |
| Matching Placebo for Upadacitinib + Upadacitinib | AbbVie | Phase 3 | 77 |
| Adalimumab + Placebo | AbbVie | Phase 3 | 77 |
| Upadacitinib + Placebo for Upadacitinib | AbbVie | Phase 3 | 77 |
| Placebo + ABT-494 | AbbVie | Phase 2 | 52 |
| ABT-494 | AbbVie | Phase 2 | 52 |
| Risankizumab + Comparator | AbbVie | Pre-clinical | 23 |
| placebo for risankizumab + risankizumab IV + risankizumab SC | AbbVie | Phase 3 | 77 |